Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Accounts Payables: 2012-2024

Historic Accounts Payables for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $304.3 million.

  • Ptc Therapeutics' Accounts Payables fell 9.87% to $303.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $303.1 million, marking a year-over-year decrease of 9.87%. This contributed to the annual value of $304.3 million for FY2024, which is 22.37% down from last year.
  • Latest data reveals that Ptc Therapeutics reported Accounts Payables of $304.3 million as of FY2024, which was down 22.37% from $392.0 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Accounts Payables ranged from a high of $392.0 million in FY2023 and a low of $242.2 million during FY2020.
  • Its 3-year average for Accounts Payables is $338.9 million, with a median of $320.4 million in 2022.
  • Per our database at Business Quant, Ptc Therapeutics' Accounts Payables soared by 52.04% in 2020 and then declined by 22.37% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Accounts Payables (Yearly) stood at $242.2 million in 2020, then climbed by 19.25% to $288.8 million in 2021, then grew by 10.94% to $320.4 million in 2022, then grew by 22.35% to $392.0 million in 2023, then dropped by 22.37% to $304.3 million in 2024.